Solventum to sell purification and filtration business to Thermo Fisher for $4.1 bln.

• Solventum Corporation to sell purification and filtration business to Thermo Fisher for $4.1 billion • Water filtration business excluded from sale • Cash consideration reduced to $4.0 billion • Transaction expected to close soon • Digital data not mentioned in article

Solventum Corporation (NYSE:SOLV), a global leader in innovative medical technology and solutions, has announced plans to sell its Purification & Filtration segment to Thermo Fisher Scientific (NYSE:TMO) for $4.1 billion. The transaction, which excludes the company's Drinking Water Filtration segment, is expected to close soon. The cash consideration for the sale has been reduced to $4.0 billion, with the remaining portion of the transaction being paid in Thermo Fisher shares [1].

Solventum Corporation has been performing strongly, with its Q2 2025 results showing consecutive quarters of positive volume growth. The company reported sales of $2.2 billion, up 3.9% year-over-year (YoY), and an adjusted EPS of $1.69, beating market expectations. The company also raised its full-year guidance for 2025, expecting organic sales growth of 2.0%-3.0% and adjusted EPS of $5.80-$5.95 [1].

Following the strong quarterly performance, Piper Sandler raised its price target on Solventum Corporation from $87 to $94, maintaining an 'Overweight' rating. Wells Fargo, however, maintained its 'Hold' rating with a $79 target. Solventum Corporation has confirmed its free cash flow guidance of $450-$550 million for 2025 [1].

The sale of the Purification & Filtration segment is part of Solventum's strategic plan to focus on its core strengths and growth opportunities in the medical technology and solutions sector. The transaction is expected to enhance Solventum's financial position and provide it with a more focused platform for future growth.

References:
[1] https://finance.yahoo.com/news/solventum-corporation-solv-reports-q2-034059620.html